Lilly’s GLP-1 Direct-To-Consumer Move, Changes The “Game Changer” Game
In his latest Forbes Online commentary, Lilly’s GLP-1 Direct-To-Consumer Move, Changes The “Game Changer” Game, Steve Brozak describes how a class of drugs, intended to treat Type 2 diabetes patients, has become a fad drug for people who want to lose weight to look good. This has transformed the market for a drug intended for a specific purpose into a multi-billion dollar market and introduces the potential for serious, life-long disabilities afflicting millions of Americans.
Read More about Lilly’s GLP-1 Direct-To-Consumer Move, Changes The “Game Changer” Game